Using WinLevi (Clascoterone) for Seborrheic Dermatitis and Acne
    Treatment 2/4/2024

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💊 Dutasteride (oral)
    the tone is 😐 neutral.

    Other terms

    Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.
    View this post in the Community →

    Similar Community Posts Join

    5 / 63 results

      community Androgenetic alopecia is a skin disease: DHT-mediated skin disorders

      in Research/Science  65 upvotes 1 year ago
      Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

      community Started Finasteride almost three months ago and I'm upset

      in Update  153 upvotes 8 months ago
      A user started taking finasteride three months ago to treat hair loss and unexpectedly cleared their acne, which they had been struggling with since age 12. The conversation includes others sharing their experiences with finasteride, its effects on acne and hair loss, and mentions a related treatment, clascoterone, for acne and hair loss.

      community Only 10 more days until cassiopea releases their 12 month results for CB-03-01 our best hope of an alternative to finasteride

      in Finasteride  151 upvotes 5 years ago
      The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

      community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA

      in Research/Science  65 upvotes 4 years ago
      The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

    Related Research

    5 / 5 results